#ncyt #alnov #novacyt

Thread:

Summary and vision of the rns "Advances in Research & Development"

- NPT
- Promate
- rt-lamp
- antigen test
- Danish strain test
- it-is production
- conclusion

1/8
Npt:

More than convincing results on a large sample:

- S&S greater than 99%
- Quick results
- mid-nose sample

We can calmly assume:

➡️ a contract with nursing homes will arrive
➡️That the contract with the NHS will enter phase 2

2/8
Promate and NPT:

New reagents:

- simplified use
- less reagents needed and lyophilized
- reduction of the duration of a test
- viral inactivation: less protection needed

➡️ Facilitate the use of Qs in small hospitals and nursing homes
➡️ New Contracts

3/8
Development of an rt-lamp test:

➡️ Test duration less than 20min
➡️ Lower cost
➡️ Other outlets (emergencies, hospitals, etc.)

This will allow #novacyt to reach a different market and gain other market share.

+ Partner searches!

4/8
Development of a serological antigen test:

➡️ Look for IgG antibodies = those that last over time
➡️ New market share for #novacyt: rapid tests
➡️ Could be used in vaccine advances!

5/8
New Danish strain test (mink):

Vaccines in development may have problems with mutations in the virus.

Being able to detect this mutation precisely will be of great help to vaccine developers and track the spread of this mutation.

6/8
It-is production:

The production is now more than 1500 / month against 300 a month ago

➡️ Supply all #novacyt customers: oem, distributors, UN, UNICEF, NHS, nursing homes.
➡️ Production can always increase
➡️ Strong increase in turnover to be expected

7/8
With new products, patents (= lower taxes) etc, #novacyt #alnov Strengthens its position and its place on the covid testing market, and also prepares its future in the diseases targeted during GA.

This is only the start of this transformation of #ncyt!

8/8
You can follow @Larry64450205.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.